SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as the crypto market experiences volatility, sparking debates about potential bottom levels and the impact of large holders like MicroStrategy. Community discussions range from calling it a "pedo ponzi coin" to anticipating a surge to $200K, highlighting the highly polarized sentiment around its future. Investors are closely watching for key support levels and potential market corrections.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending downwards amidst Bitcoin's recent volatility, sparking debates about its correlation with BTC and potential risks. Community discussions range from concerns about margin calls and possible delisting to speculation on a potential bottom, with some traders eyeing a bounce while others foresee further declines. The stock's performance is closely tied to Bitcoin's price movements and Michael Saylor's strategy, leading to heightened uncertainty and a wide range of opinions.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending as investors discuss its correlation to Ethereum's price movements and upcoming earnings, with many expressing concerns over recent price drops and the impact of crypto market volatility. The community is actively debating the influence of figures like Tom Lee and Cathie Wood, while also pondering potential catalysts such as staking announcements and possible market manipulation. Discussions include BMNR's NAV, potential risks, and the overall sentiment surrounding crypto investments.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp ($BULL) is trending following earnings, with community members pointing to strong revenue growth and a significant EPS beat. Despite positive results, some express concern about the overall market conditions and potential dilution, while others remain bullish, anticipating future upgrades and a rise in stock price. Discussions also revolve around institutional interest and comparisons to similar companies like Robinhood.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending amid volatility, with investors reacting to a UBS price target increase and broader market concerns. Community discussions revolve around whether the recent selloff presents a buying opportunity or signals an overbought condition, especially with Nvidia's earnings on the horizon. Sentiment is mixed as some anticipate a continued rally driven by AI memory demand, while others foresee a deeper correction.

Blockchain-on-Blockchain (BOB) is a new blockchain built on top of another blockchain called ICP. It's like a special layer on an existing system. BOB creates a secure digital record book that uses ICP's network for safety. BOB uses a system called 'proof-of-on-chain-work': You deploy your own smart contract (canister) at bob.fun. This program solves math problems (hashes). Main computers (mother nodes) give out these problems. Miners solve the problems and tell the mother node. If correct, the mother node adds a new block to the blockchain. The winning miner gets BOB tokens as a reward.

$BOB is trending as a novel token on the ICP blockchain, drawing comparisons to an early-stage Bitcoin due to its limited supply and halving schedule, sparking community interest. Discussions revolve around its potential for significant growth, particularly in relation to the ICP ecosystem, with some viewing it as a way to support the network. The community is closely watching upcoming halving events and their potential impact on price.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

LEU is trending due to a multi-billion dollar investment in its uranium enrichment expansion, sparking bullish sentiment. The community is discussing the potential for a short squeeze given the high short interest and small float. Broader context includes rising interest in nuclear energy, driven by AI and national security concerns.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk ($SNDK) is trending due to significant volatility and a recent price surge driven by optimism around the memory market and AI data center demand. The stock experienced a large pullback after hitting new highs, sparking debates about its valuation, potential overextension, and whether it's primed for a bounce or further decline. Community members are actively discussing swing trading opportunities versus long-term holds, and speculating about possible acquisitions.

ETF Opportunities Trust - T-REX 2X Long BMNR Daily Target ETF

T-REX 2X Long BMNR Daily Target ETF

The T-REX 2X Long BMNR Daily Target ETF ($BMNU) is trending as traders discuss its potential for gains amidst fluctuations in Ethereum ($ETH) and its underlying asset, Bit Mining ($BMNR). Community chatter revolves around the ETF's leveraged exposure, with some expressing concerns about potential reverse splits and others anticipating a significant rally if Ethereum rebounds. The conversation also highlights the debate around its tracking accuracy and suitability for short-term trading.

Copart, Inc. engages in the provision of online auctions and vehicle remarketing services. The firm offers vehicle sellers a full range of services to process and sell vehicles primarily over the internet through Virtual Bidding Third Generation Internet auction-style sales technology. It sells vehicles principally to licensed vehicle dismantlers, rebuilders, repair licensees, used vehicle dealers, exporters and at certain locations, and the public. The company’s services include online seller access, salvage estimation services, estimating services, end-of-life vehicle processing, virtual insured exchange, transportation services, vehicle inspection stations, on-demand reporting, DMV processing, and vehicle processing programs. It operates through the United States and International segments. The company was founded by Willis J. Johnson in 1982 and is headquartered in Dallas, TX.

Copart, Inc.

Copart's recent earnings are driving discussion, with the community analyzing whether the results justify the stock's valuation amid strong revenue and EPS figures. Community members are closely monitoring the company's performance, particularly its cash position and potential for strategic acquisitions or buybacks. The stock's potential to outperform in a correcting market, and its position within the broader vehicle auction and e-commerce landscape, also remain key talking points.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>CEO John C. Jacobs noted that over the past eight quarters, the company has achieved approximately $1.1 billion in non-dilutive cash flow, including $800 million from its partnerships.</li><li>For the third quarter, the company reported total revenue of $70 million, including $48 million from Sanofi, $6 million from Takeda, and $2 million from other partners.</li><li>Novavax now expects full-year adjusted revenue in the $1.04 billion to $1.06 billion range. &nbsp;</li></ul>Novavax (NVAX) CEO John C. Jacobs on Thursday detailed the company’s efforts beyond its COVID-19 vaccine, including expanding partnerships with Sanofi and Takeda.“Our new strategy is centered on amplifying the impact of our technology platform through collaborations with other biopharmaceutical companies and a new diversified pipeline, and this represents a strategic and thoughtful departure away from a single focus on the resource-intense commercialization of one product, our COVID-19 vaccine,” the CEO said.Jacobs noted that over the past eight quarters, the company has achieved approximately $1.1 billion in non-dilutive cash flow, including $800 million from its partnerships in the form of upfront payments and milestones earned to date.The company recently expanded on its Sanofi partnership to include its Matrix-M adjuvant in Sanofi’s pandemic influenza vaccine candidate program. It also renegotiated its deal with Takeda in a bid to grow revenues from the latter's activities involving Nuvaxovid vaccine in Japan.<h2 class="st-heading-2">Q3 Numbers</h2>For the third quarter, the company <a href="https://stocktwits.com/symbol/NVAX">reported</a> total revenue of $70 million, including $48 million from Sanofi, $6 million from Takeda, and $2 million from other partners. This marks a dip from the $80 million reported in the corresponding quarter of 2024, but above an analyst estimate of $44.87 million.The company now expects full-year adjusted revenue in the $1.04 billion to $1.06 billion range, up from its previous guidance of $1 billion to $1.05 billion. This is primarily owing to better than previously expected licensing, royalty, and other revenue.The company’s loss per share came in at $1.25 in the third quarter, above an expected loss of $1.13.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:623/57;" src="data:image/png;base64,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" width="623" height="57" alt="NVAX's Sentiment Meter and Message Volume as of 1:12 p.m. ET on Nov. 6, 2025 | Source: Stocktwits"><figcaption>NVAX's Sentiment Meter and Message Volume as of 1:12 p.m. ET on Nov. 6, 2025 | Source: Stocktwits</figcaption></figure>NVAX stock is down by about 4% this year and by about 14% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-reportedly-refrains-from-backing-down-in-metsera-acquisition-battle-sweetens-bid-further/cL2twEeRER8">Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Novavax Sees Higher Revenue From Partners For Full-Year, Raises Revenue Guidance

The company recently expanded on its Sanofi partnership to include its Matrix-M adjuvant in Sanofi’s pandemic influenza vaccine candidate program.

Equity

The company recently expanded on its Sanofi partnership to include its Matrix-M adjuvant in Sanofi’s pandemic influenza vaccine candidate program and renegotiated its deal with Takeda in a bid to grow revenues from the latter's activities involving Nuvaxovid vaccine in Japan. 

<ul class="summary-bullets"><li>In Q3, Ibsrela saw highest demand since launch and recorded revenue of $78.2 million, marking a growth of 92%.</li><li>Ardelyx’s net loss in the quarter, however, was $1 million, compared to net loss of $0.8 million reported in the corresponding quarter of 2024.</li><li>The company is now looking forward to filing an investigational new drug submission to the FDA for its early-stage candidate RDX10531 in 2026.&nbsp; &nbsp;</li></ul>Ardelyx shares soared 22% in Friday’s premarket session after the company raised guidance for its irritable bowel syndrome drug Ibsrela, which saw the highest demand in the third quarter (Q3).“IBSRELA continues to outperform and is the foundation of our portfolio and the main engine for Ardelyx's future growth,” CEO Mike Raab said on the company’s earnings call on Thursday.“Demand growth is broad-based and demonstrates how vital this therapy is for patients. We expect this momentum to continue through Q4 and beyond, and as a result, we are raising our guidance,” he added.<h2 class="st-heading-2">Revised Guidance, Q3 Fineprint</h2>The company now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-reports-third-quarter-2025-financial-results-and">expects </a>revenue to be between $270 million and $ 275 million from Ibsrela for the full year. In the third quarter, the drug generated revenue of $78.2 million, marking a growth of 92%, and accounting for 74% of the company’s total product revenue for the period.U.S. revenue for Xphozah, used to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis, was $27.4 million in Q3 despite dynamic market situations, the company said. Ardelyx now expects continued growth in the fourth quarter for the drug.Total revenue in the quarter, including product and licensing revenue, came in at $110.3 million, above an analyst estimate of $100.54 million. Net loss in the quarter was $1 million, slightly wider than the $0.8 million net loss reported in the corresponding quarter of 2024.<h2 class="st-heading-2">Future Pipeline</h2>In the third quarter, Ardelyx began developing RDX10531, an early-stage drug candidate. The company is now looking forward to filing an Investigational New Drug submission with the U.S. Food and Drug Administration for the candidate in 2026, to initiate trials in humans.“We are committed to building a broad, sustainable pipeline, capitalizing first on an internal asset while, in parallel, we explore external opportunities,” Raab said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARDX">ARDX stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/57;" src="data:image/png;base64,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" width="623" height="57" alt="ARDX's Sentiment Meter and Message Volume as of 8:50 a.m. ET on Oct. 31, 2025 | Source: Stocktwits"><figcaption>ARDX's Sentiment Meter and Message Volume as of 8:50 a.m. ET on Oct. 31, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sees the stock hitting a per-share price of $7 today.<stembedurl>https://stocktwits.com/badgermobile/message/634454149</stembedurl>Another expressed optimism about the CEO saying on the earnings call that it is open to external business opportunities.<stembedurl>https://stocktwits.com/Dragan7/message/634447443</stembedurl>ARDX stock is down 1% year-to-date and by approximately 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-shareholder-gavin-baker-supports-elon-musk-1-trillion-pay-plan/cLGqGXNR3Ul">Atreides’ Gavin Baker Backs Elon Musk’s $1T Tesla Pay Deal Despite Broad Opposition</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ardelyx logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Ardelyx Shares Soar Premarket As CEO Sees Continued Demand For Blockbuster Drug Ibsrela

The company now expects revenue from Ibsrela to be between $270 million and $275 million for the full year.

<ul class="summary-bullets"><li>ADX-629 was administered orally for one month in four patients with mild to moderate alcohol-associated hepatitis in the study.</li><li>Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation, the company said.&nbsp;</li><li>The company has, however, &nbsp;now discontinued clinical development of ADX-629 pending further investigator-sponsored clinical testing in Sjögren-Larsson Syndrome.&nbsp; &nbsp;</li></ul>Aldeyra Therapeutics, Inc. (ALDX) on Tuesday announced that its experimental drug candidate ADX-629 demonstrated statistically significant improvement in liver function in patients with alcohol-associated hepatitis in a mid-stage trial.ADX-629 was administered orally for one month in four patients with mild to moderate alcohol-associated hepatitis in the study. Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-positive-results-phase-2-clinical">said.</a>No serious adverse events were reported in the trial, the company noted. Furthermore, no adverse events were deemed related to its experimental drug, it added.<h2 class="st-heading-2">Plans Ahead</h2>The company has, however, &nbsp;now discontinued clinical development of ADX-629 pending further investigator-sponsored clinical testing in Sjögren-Larsson Syndrome, a rare genetic disorder.CEO Todd C. Brady said that the company will share details of the recent trial in the future and will now focus its pipeline on ADX-248 and ADX-246 for the treatment of immune-mediated diseases.While ADX-248 is being studied in the treatment of metabolic inflammation, including obesity and hypertriglyceridemia, ADX-246 is being studied for the treatment of dry form of age-related macular degeneration.Aldeyra is committed to developing a robust pipeline of novel therapeutics in a fiscally prudent manner to maintain growth, the CEO noted.The company now expects cash, cash equivalents, and marketable securities to provide operational runway into the second half of 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ALDX">ALDX stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.ALDX stock is down by 0.5% this year and by about 12% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-registrations-slumped-nearly-19-percent-in-eu-in-september-despite-rising-ev-demand/cLGjW7LR3HL">Tesla Registrations Slumped Nearly 19% In EU In September Despite Rising EV Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Aldeyra Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Aldeyra Reports Positive Mid-Stage Data For Liver Drug, Discontinues Further Development

Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation in the study, the company said. 

<ul class="summary-bullets"><li>Inhibrx Biosciences announced that its drug Ozekibart yielded positive results in a registrational trial for a rare type of bone cancer.</li><li>In the study, Ozekibart achieved a 52% reduction in the risk of disease progression or death compared to placebo, more than doubling median progression-free survival to 5.52 months.</li><li>According to Inhibrx, Ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma. &nbsp;</li></ul>Shares of Inhibrx Biosciences (INBX) jumped over 62% in the pre-market session on Friday after the company announced that its drug Ozekibart yielded positive results in a registrational trial for a rare type of bone cancer.The company investigated Ozekibart as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma, a rare type of bone cancer that develops in the cartilage cells, most often affecting the pelvis, thigh, or upper arm.<h2 class="st-heading-2">What Was Observed In The Study?</h2>In the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://inhibrxbiosciences.investorroom.com/2025-10-23-Inhibrx-Biosciences-Reports-Positive-Topline-Results-from-its-Registrational-Trial-of-Ozekibart-INBRX-109-in-Chondrosarcoma-and-Provides-Updates-on-Colorectal-Cancer-and-Ewing-Sarcoma-Expansion-Cohorts">study</a>, Ozekibart achieved a 52% reduction in the risk of disease progression or death compared with placebo, more than doubling median progression-free survival to 5.52 months versus 2.66 months with placebo. Progression-free survival (PFS) is the time a patient lives with a disease without worsening, from the start of treatment until disease progression or death.According to Inhibrx, Ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma.<h2 class="st-heading-2">Safety Concerns</h2>Ozekibart was generally well tolerated, with a manageable safety profile, the company said. However, one liver damage-related fatal event occurred early in the study, it noted. The company mitigated the risk during the course of the trial by excluding patients with severe liver impairment and by implementing close monitoring during early treatment cycles, thereby reducing the overall incidence of liver-related treatment-related adverse events, it added.Inhibrx is also studying the drug in colorectal cancer and ewing sarcoma in combination with other drugs. While colorectal cancer is a cancer that forms in the colon or rectum, ewing sarcoma is a type of cancer that forms in the bone or soft tissue.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/INBX"> INBX stock </a>jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels. Retail chatter around the stock jumped about 985% over the past 24 hours, according to Stocktwits data.<figure class="image"><img style="aspect-ratio:584/62;" src="data:image/png;base64,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" width="584" height="62" alt="INBX's Sentiment Meter and Message Volume as of 7:00 a.m. ET on Oct. 24, 2025 | Source: Stocktwits"><figcaption>INBX's Sentiment Meter and Message Volume as of 7:00 a.m. ET on Oct. 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to rally as high as over $70, citing the company’s first-mover advantage in developing drugs for chondrosarcoma.<stembedurl>https://stocktwits.com/spaumaki/message/633545900</stembedurl>INBX stock is up 84% this year.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/reliance-increases-crude-imports-from-middle-east-u-s-amid-russian-crude-sanctions-report/cLGJZgVR3so">Reliance Increases Crude Imports From Middle East, U.S. Amid Russian Crude Sanctions: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Is INBX Stock Rising Today?

Inhibrx Biosciences announced that its drug Ozekibart yielded positive results in a registrational trial for a rare type of bone cancer.

EMJ Capital President Eric Jackson on Wednesday expressed optimism about Sana Biotechnology (SANA) stock, saying it could become “the next 100-bagger platform.”SANA shares traded 35% higher at the time of writing.Jackson <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/ericjackson/status/1978460243001782649">took</a> to the social media platform X, opining that <a href="https://stocktwits.com/symbol/SANA">SANA stock</a> would eventually explode, and highlighted the company’s various achievements, including its work in type 1 diabetes treatment. In January, Sana said that following a transplant of an allogeneic primary islet cell therapy into a patient with type 1 diabetes, they started producing insulin. The therapy was engineered with Sana’s hypoimmune (HIP) technology, enabling the transplantation without the need for immunosuppression.<figure class="image"><img style="aspect-ratio:592/407;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_15_at_11_35_05_AM_png_c72bd5dfe0.webp" alt="Screenshot 2025-10-15 at 11.35.05 AM.png" width="592" height="407"><figcaption>Screenshot of Jackson's X Post</figcaption></figure>Transplants generally require lifelong immunosuppression, but Sana’s technology removes the need for them, Jackson noted. ‘That’s not hype — it’s human proof that Sana’s “hypoimmune” cells can hide from the immune system and work normally. If it works in diabetes, it could work for liver, heart, muscle, or brain cells next,’ he wrote, expressing hopes for the technology powering future therapies for autoimmune diseases, cancer, and even organ regeneration.Jackson further highlighted that the biotech company’s balance sheet is solid and added that he was long on SANA stock. He also highlighted several upsides, including 9 million people with diabetes worldwide who might benefit from the treatment.“If Sana’s therapy costs $100K per patient (typical for cell therapy) and reaches only 10% of them, that’s $90B in revenue potential over time,” Jackson said.On Stocktwits, retail sentiment around SANA jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘high’ to ‘extremely high’ levels.SANA stock has more than tripled this year and gained about 41% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-unveils-expanded-facility-in-texas-aimed-at-doubling-production-of-hyperkalemia-drug/ch6nzBiR3No">AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sana Biotech Stock Jumps A Whopping 35% After Eric Jackson Calls It ‘Next 100-Bagger Platform’

Jackson added that he was long on the stock, while highlighting that the biotech company’s balance sheet is solid.

Enanta Pharmaceuticals (ENTA) on Monday announced that its mid-stage trial evaluating the efficacy and safety of Zelicapavir in outpatient adults with acute Respiratory Syncytial Virus (RSV) infection who are at high risk of complications failed to meet the primary endpoint.Shares of the company, however, rose 58% by Monday afternoon. Notably, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-positive-topline-results-its">stated</a> that a clinically meaningful improvement in time to complete resolution of all 13 RSV symptoms was observed for Zelicapavir compared to placebo, with a benefit of 2.2 days for the overall efficacy population and 6.7 days for patients with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), or aged 75 and older.A lower hospitalization rate was observed for patients treated with Zelicapavir compared to placebo, and Zelicapavir demonstrated a robust antiviral effect, it added.The study, however, failed in its primary endpoint of lowering the time to resolution of lower respiratory tract disease symptoms to mild. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ENTA">ENTA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_1_22_50_PM_png_995d6b1542.webp" alt="ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits" width="576" height="65"><figcaption>ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user cheered the rally.<stembedurl>https://stocktwits.com/JL_TradeZ/message/630342393</stembedurl>Another noted that though the trial missed the primary endpoint, the rest of the data “looks great.”<stembedurl>https://stocktwits.com/heyupikachu1821/message/630357384</stembedurl>Enanta said on Monday that Zelicapavir demonstrated a favorable safety profile in the trial and was well-tolerated. The goal of the study was to inform the design of a late-stage trial, including populations and endpoints, and no adverse events led to treatment discontinuation or study withdrawal in the Zelicapavir group.“We believe the totality of these data provides strong rationale for further clinical advancement of zelicapavir. Importantly, we identified multiple potential registrational endpoints for a Phase 3 trial,” said Chief Medical Officer Scott T. Rottinghaus.RSV is a common respiratory virus that infects the lungs and respiratory tract. Older adults are at significantly increased risk of severe illness due to the natural weakening of the immune system with age.ENTA stock has more than doubled this year and gained by about 20% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kala-bio-stock-plunges-after-experimental-drug-fails-study/chDuP3wR3Ja">Kala Bio Stock Just Plunged 89% Today – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, capsules are seen in a hand dressed in a medical glove with the Enanta Pharmaceuticals logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update

The company reported that a lower hospitalization rate was observed in patients treated with Zelicapavir compared to those treated with placebo, and the drug demonstrated a robust antiviral effect.

Larimar Therapeutics, Inc. (LRMR) on Monday announced positive data from an ongoing long-term open-label study evaluating daily subcutaneous injections of Nomlabofusp in participants with Friedreich’s Ataxia.Friedreich's Ataxia (FA) is a rare, inherited disorder causing progressive damage to the nervous system, leading to symptoms like poor coordination, difficulty walking, and sensory loss, as well as heart disease and scoliosis. It is caused by a mutation in the FXN gene, resulting in a deficiency of the mitochondrial protein frataxin.In the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/29/3157570/0/en/Larimar-Therapeutics-Announces-Positive-Data-from-Ongoing-Long-term-Open-Label-Study-and-Updates-to-Nomlabofusp-Program-for-Friedreich-s-Ataxia.html">study,</a> an increase in skin frataxin (FXN) levels was observed with short- and long-term daily Nomlabofusp. All ten participants with data at six months achieved skin FXN levels over 50% of median levels in healthy volunteers, the company stated. It added that consistent directional improvement across multiple clinical outcomes was also observed after a year of Nomlabofusp treatment.“These new data, as well as the improvement in abnormal lipid profiles observed in prior completed studies, provide support that nomlabofusp increases FXN in patients with FA and that the strategy of FXN replacement has the potential to result in a clinical benefit,” said CEO Carole Ben-Maimon.Shares of the company tumbled 47% in the pre-market session after the company reported that anaphylaxis, or a severe allergic reaction, was observed in seven participants in the open-label study, and they were subsequently withdrawn from the study. Most instances of anaphylaxis occurred on the initial day of administration and most within the first six weeks of dosing, it noted.Other discontinuations in the study included three cases of generalized urticaria, one seizure, one vasovagal event, and two non-treatment-related discontinuations, it said.The company said that it consulted experts and decided to modify its starting dose regimen after the two most recent cases of anaphylaxis. The U.S. Food and Drug Administration has agreed with the approach, the company said. Larimar is looking to submit an application for approval of Nomlabofusp to the FDA in the second quarter of 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LRMR">LRMR stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.LRMR stock is down by 2% this year and by 42% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-lobby-announces-new-website-to-connect-patients-with-manufacturer-direct-patient-programs/chDuciYR3JJ">Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Programs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study

The company said that anaphylaxis or a severe allergic reaction was reported in seven participants in the open-label study evaluating Nomlabofusp in participants with Friedreich’s ataxia. 

Harrow (HROW) announced on Friday that it has entered into an agreement to acquire privately held Melt Pharmaceuticals for an undisclosed price.While Harrow is a provider of ophthalmic disease management solutions, Melt Pharmaceuticals is focused on developing non-opioid therapies for sedation during medical procedures. Melt was spun out of Harrow in January 2019.The acquisition will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.harrow.com/news-releases/news-release-details/harrow-acquire-melt-pharmaceuticals">include</a> Melt’s lead investigational therapy, MELT-300, a sublingually delivered formulation of a fixed dose of Midazolam (3mg) and Ketamine (50mg) designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration.Shares of Harrow jumped 4% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HROW">HROW stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.MELT-300 was found to be statistically superior to both sublingual Midazolam alone and placebo in providing successful procedural sedation in a late-stage study. A recently completed cardiac safety study also indicated that MELT-300 did not alter normal heart rhythm, supporting the therapy’s safety profile. Harrow now plans to submit a new drug application to the U.S. Food and Drug Administration for the sedative in 2027, and is eyeing a commercial launch in the U.S. in 2028.If the FDA approves MELT-300, the company intends to discontinue the MKO Melt sedation product, marketed through its ImprimisRx subsidiary, for cataract surgeries. The company also sees potential for MELT-300 to be used in other procedures, including claustrophobia during MRIs, sedation for colonoscopies, dental procedures, gastroenterology procedures, and other interventions.The closing of the merger transaction, however, is subject to customary closing conditions, including approval by Melt shareholders, Harrow added.HROW stock is up 43% this year and by about 9% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/costco-draws-mixed-reactions-from-wall-street-despite-q4-beat-here-is-why/chDVjZGR3eX">Costco Draws Mixed Reactions From Wall Street Despite Q4 Beat: Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Harrow To Acquire Sedation Solutions Developer Melt Pharmaceuticals – More Details Inside

The acquisition will include Melt’s lead investigational therapy, MELT-300, designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration. 

Shares of Rambus, Inc. (<a class="mention" data-mention="$RMBS" data-symbol-id="RMBS" href="https://stocktwits.com/symbol/RMBS" target="_blank">$RMBS</a>), a provider of Double Data Rate (DDR) memory interface chips, rose sharply early Tuesday, thanks to a positive analyst action.In a note published late-Tuesday, Baird analyst Tristan Gerra initiated coverage of Rambus with an&nbsp;‘Outperform’ rating and a $90 price target, which suggests scope for about 58% upside potential.The analyst noted that Rambus’ technology and IP is central to the artificial intelligence (AI)-driven performance increase in data centers. "Rambus is at the center of our 2025 semiconductor investment themes, which include AI memory, processors and optical systems," he said.&nbsp;Rambus has over 75% revenue exposure to data centers with AI becoming a major component of growth, Gerra said.&nbsp;He noted that the company is first to market with the October announcement of the "industry-first complete memory interface chipset for Gen 5 DDR5 RDIMM and next-generation MRDIMM." These bring much higher data transfer rates, lower latency and power consumption, he added.With the lineup, the company is poised to see a significant total addressable market expansion opportunity, Gerra said.The analyst sees major license deals with leading AI chip makers into the next year due to the HBM4 controller IP it announced in September that is expected to ramp in 2026.&nbsp;Rambus is poised to see significant growth, content increase, and share gains ahead, Baird said, adding that its data center chipset opportunity is estimated at $1.5 billion.<figure class="image"><a href="https://stocktwits.com/symbol/RMBS"><img style="aspect-ratio:631/138;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/rmbs_sentiment_5078361ebc.png" alt="rmbs-sentiment.png" width="631" height="138"></a><figcaption>RMBS sentiment and message volume November 26, 2024, as of 10:30 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits platform, retailers turned ‘bullish’ (67/100) from a ‘neutral’ disposition a day ago, with message volume rising to ‘high’ level.At last check, Rambus was up 3.27% to $58.75.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Related Link:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/zoom-video-reports-beat-and-raise-q3-2025/cJIWZvyRgq">Zoom Video Stock Slumps Despite Beat-and-Raise Q3 But Retail Stays Connected</a>

Rambus shares have underperformed the broader market and the semiconductor industry this year.

Rambus Stock Powers Up After Memory Chipmaker Snags A Bullish Rating: Retail Upbeat

Rambus’ technology and IP is central to the artificial intelligence-driven performance increase in data centers, said Baird analyst Tristan Gerra.

Expectations are muted as Bath &amp; Body Works, Inc. (<a class="mention" data-mention="$BBWI" data-symbol-id="BBWI" href="https://stocktwits.com/symbol/BBWI" target="_blank">$BBWI</a>), a retailer of personal care and home fragrance products, prepares to report its third-quarter results before the market opens on Monday.Analysts, on average, expect the Columbus, Ohio-based company to report third-quarter adjusted earnings per share (EPS) of $0.47 on net sales of $1.58 billion. This compares to the year-ago numbers of $0.48 and $1.56 billion, respectively. The company guided to flat to a 2.5% increase in net sales, translating to $1.56-$1.6 billion.&nbsp;Ahead of the results, Citigroup said it expects above-consensus adjusted EPS due to a slightly stronger gross margin and lower spending, the Fly&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://thefly.com/news.php?symbol=BBWI">reported.</a> While conceding that the third quarter was another difficult quarter to drive sales, due to consumers remaining price-sensitive and the lack of big promotions to drive traffic, the firm said the second-half guidance is conservative enough.&nbsp;Citi believes that the fourth quarter is the best opportunity for the company to deliver upside to sales guidance this year. The firm has a Neutral rating and $35 price target for the stock. The risk/reward is skewed positive, going into the print, it said.Last week, JPMorgan analysts reduced its price target for the shares from $39 to $35.In early November, Bath &amp; Body Works announced a regular quarterly cash dividend of $0.20, payable on Dec. 6, to shareholders at the close of business on Nov. 22.The running quarter’s guidance is important, as it encompassed the holiday season. The forecast for this year’s industry-wide holiday sales is bright, with Bain &amp; Company<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bain.com/insights/2024-holiday-shopping-inside-latest-retail-sales-snap-chart/"> noting</a> a 5.4% year-on-year increase in October compared to September's 3.1% growth.&nbsp;"Santa’s sleigh has kicked into high gear for the start of the season," the firm said. Online sales grew 9.4%, in line with expectations, while in-store sales climbed a better-than-expected 4%, it added.Bath &amp; Body Works currently expects full-year net sales to fall by 2%-4%, with the 53rd week in 2023 representing a 100-basis-point headwind, and adjusted EPS of $3.02-$3.26.&nbsp;Bath &amp; Body Works shares have fallen about 27.33% for the year-to-date period.The average analysts’&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.tipranks.com/stocks/bbwi/forecast">price target&nbsp;</a>for Bath &amp; Body Works stock is $41.20, suggesting roughly 34% upside potential.<figure class="image"><a href="https://stocktwits.com/symbol/BBWI"><img style="aspect-ratio:637/130;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/bbwi_sentiment_064b8def79.png" alt="bbwi-sentiment.png" width="637" height="130"></a><figcaption>BBWI sentiment and message volume November 24, 2024, as of 9:40 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, retail sentiment was ‘neutral’ (49/100), a deterioration from the ‘bullish’ mood that prevailed a day ago, while message volume was ‘normal.’The stock ended Friday’s session up 0.52% at $30.71.For updates and corrections email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/govx-siga-ebs-cmrx-stocks-gain-who-declares-who-public-health-emergency/cJId4JgRge">GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks</a>

The holiday quarter got off to a promising start, with a strong October, going by Bain & Co.’s estimates

Bath & Body Works Analyst Cautious Ahead Of Q3 Print: Retail Sentiment Deflates

Price-sensitive consumers and a lack of big promotional drive dampen outlook for Bath & Body Works’ third quarter, Citi said.

IWV
BlackRock Institutional Trust Company N.A. - iShares Russell 3000 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWV News

IWVBlackRock Institutional Trust Company N.A. - iShares Russell 3000 ETF